Payers

Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine

Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.

Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.

An independent review of BTK inhibitors in mantle cell lymphoma finds areas are of strength both second-generation therapies, as authors call for clinical trials to inform guidelines.

NCCN survey finds universal, persistent generic drug shortages; coping tactics stretch teams as looming tariffs threaten more supply disruptions.

The action comes after an advisory panel recommended against approval, saying evidence from the did not support a “clinically meaningful benefit."

Previous research has tied the loosening of permit-to-purchase and concealed carry laws to increased firearm suicide rates.

Matched real-world MCL data shows acalabrutinib and zanubrutinib lower atrial fibrillation vs ibrutinib, with fewer bleeding events.

How tebentafusp, a BiTE bispecific T-cell engager, changes metastatic uveal melanoma care—HLA testing, dosing, safety and access tips for clinics.

John Kitchens, MD, explores how GLP-1s, novel drug pipelines, and Medicaid access gaps are shaping the future of DME management.

A target trial emulation found GLP-1 RA initiation was associated with a 21% lower 3-year fragility fracture risk compared with DPP-4 inhibitor therapy.

Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at the practice level.

Closed-loop social care networks move beyond referrals, proving statewide scale can cut ED use and Medicaid costs while tracking real outcomes.

Anti-VEGF has maxed out in diabetic macular edema (DME), but Ang-2 and Wnt pathway approaches could target disease differently, said John Kitchens, MD.

CMS proposes major Medicare reforms to ACOs, physician pay, and MIPS reporting, aiming to reward outcomes over service volume by 2029.

New data suggest epcoritamab plus R2 may win insurer coverage, delivering major QALY gains at approximately $68,000 and delaying costly progression.

A proposed 2027 CMS rule would cut 340B Drug Pricing Program payments to curb Medicare drug costs and shift savings to patients.

emtelligent turns unstructured data into coded clinical insights, powering payer and oncology workflows to improve trial screening, EHR-to-EDC transfer, and decisions.

At ESMO GI, Merck’s next-generation KRAS-inhibitor calderasib plus EGFR-targeting cetuximab and chemotherapy produce remarkable progression-free survival results for patients with previously untreated colorectal cancer.

Community Oncology Alliance AI Playbook powers digital health practice transformation, guiding teams to choose AI partners, protect data, and expand efficient care.

Summary of Nonconsensus Discussions: Bridging the Gaps in Health Equity & Access in Multiple Myeloma | May 2, 2026, Tampa, Florida

Insurance and socioeconomic factors delay optimal anti-VEGF care for diabetic macular edema, worsening vision disparities.

Clinicians and pharmacists at Temple and Penn discuss barriers to multidisciplinary obesity care, from ICD-10 coding gaps to prior authorization burdens.

SEER and Medicare data project rising DLBCL and MCL cases through 2032, intensifying payer strain and demand for Brukinsa, Calquence, and CAR-T access.

With an FDA approval for its companion diagnostic in bladder cancer, Natera extends its Treatment on MRD strategy, deferring adjuvant immunotherapy for patients with negative results for disease following surgery.